Technical Study: Teva Pharma Industries Ltd, Covidien PLC, Dynavax Technologies Corp., and Valeant Pharma Intl. Inc. PR Newswire LONDON, November 15, 2013 LONDON, November 15, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The U.S. equity market edged higher on Thursday, November 15, 2013. All three benchmark indexes posted gains, with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite gaining 0.48%, 0.35% and 0.18%, respectively. Shares in the healthcare sector fluctuated between gains and losses, even as the broader market advanced. The major movers in the sector included Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Covidien PLC (NYSE: COV), Dynavax Technologies Corp. (NASDAQ: DVAX), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). AAAResearchReports.com free coverage on TEVA, COV, DVAX, and VRX is available upon registration at: http://www.aaaresearchreports.com/register/ Teva Pharmaceutical Industries Ltd's shares fluctuated between $38.14 and $38.68 before ending the Thursday's session 0.10% lower at $38.35. A total of 5.63 million shares were traded, which is above the daily average volume of 5.15 million. Despite Thursday's decline, the company's shares have gained 2.93% in the previous three trading sessions, outperforming the S&P 500, which has gained 1.06% during the same period. Additionally, Teva Pharmaceutical Industries Ltd's stock is trading below its 50-day and 200-day moving averages of $38.62 and $38.96, respectively. Download free technical research on TEVA by signing up at: http://www.AAAResearchReports.com/TEVA111513.pdf On Thursday, Covidien PLC's stock rose 1.44%, hitting a new 52-week high of $66.27. The company's shares fluctuated between $65.15 and $66.27 before closing the day at $66.08. A total of 2.45 million shares were traded, which is above the daily average volume of 2.19 million. The company's shares have advanced 6.99% in the previous one month and 3.25% in the last three trading sessions, outperforming the S&P 500, which has gained 4.71% and 1.06% during the respective periods. Moreover, Covidien PLC's stock is trading above its 50-day and 200-day moving averages of $62.48 and $60.27, respectively. Register now and get access to free analysis on COV at: http://www.AAAResearchReports.com/COV111513.pdf Dynavax Technologies Corp.'s stock advanced 0.76% on Thursday, tracking gains in the broader market. The company's shares closed at$1.33 after oscillating between$1.29 and$1.38 during the trading session. A total of 2.92 million shares were traded, which is above the daily average volume of 2.65 million. The company's shares have gained 9.92% in the previous three trading sessions and 12.71% in the last one month, outperforming the S&P 500, which has gained 1.06% and 4.71% during the respective periods. Further, Dynavax Technologies Corp.'s stock is trading above its 50-day moving average of $1.21. Sign up and read our complimentary report on DVAX at: http://www.AAAResearchReports.com/DVAX111513.pdf Valeant Pharmaceuticals International Inc.'s stock ended the Thursday's session 1.20% lower than the previous day's price of $107.15. The company's shares oscillated between $105.03 and $107.45 before closing the day at $105.86. A total of 0.92 million shares were traded, which is below the daily average volume of 1.18 million. The company's shares have gained 0.67% in the previous three trading sessions, underperforming the S&P, 500 which has gained 1.06% during the same period. Additionally, Valeant Pharmaceuticals International Inc.'s stock is trading above its 200-day moving average of $87.71. The free report on VRX can be downloaded by signing up now at: http://www.AAAResearchReports.com/VRX111513.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AAAResearchReports.com/ SOURCE AAA Research Reports Contact: Peter F. Jones; Phone #: +1(646)396-9126; Email ID: email@example.com
Technical Study: Teva Pharma Industries Ltd, Covidien PLC, Dynavax Technologies Corp., and Valeant Pharma Intl. Inc.